Table 2.
Age at onset, comparison with previous large studies.
| The age of onset | Present study | Eujin Park (Korea) | China Nagano (Japan) | Carolin E | |
|---|---|---|---|---|---|
| Percent with causative mutation detectation | 1–3 m | 25/35 (71.4%) | 27/35 (77.1%) | 11/13 (84%) | 163/235 (69.5%) |
| 3 m−1 y | 13/29 (44.8%) | 11/25 (44%) | 8/15 (53%) | 81/163 (49.6%) | |
| 1–3 y | 21/91 (23.1%) | 40/114 (35%)* | 23/89 (26%) | 177/700 (25%) | |
| 3–6 y | 15/46 (32.6%) | 6/36 (17%) | 56/315 (17.7%) | ||
| 6–12 y | 29/72 (40.3%) | 15/36 (27.7%) | 16/52 (31%) | 19/176 (11%) | |
| 12–18 y | 3/10 (33.3%) | 2/3 (66.7%) | 3/15 (20%) | 6/28 (21.4%) | |
| CNS | NPHS1 (17/25) | WT1 (15/31) | NPHS1 (4/11) | NPHS1 (94/163) | |
| WT1 (3/25) | NPHS1 (11/31) | LAMB2 (4/11) | NPHS2 (25/163) | ||
| NPHS2 (2/25) | COQ3 (3/31) | WT1 (2/11) | WT1 (20/163) | ||
| LAMB2 (2 /25) | LAMB2 (2/31) | LAMA5 (1/11) | LAMB2 (13/163) | ||
| ADCK4 (1/25) |
CNS, congenital nephrotic syndrome.
*
The percent of causative mutation detectation rate at age of oneset of 3–6 years.